Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
Mary Szela, Abbott
S
Advertisement
ONE TO WATCH:
Mary Szela SVP, Pharma Operations, Abbott
With more than 20 years at Abbott, Szela, age 45, is making her way through the ranks. She started her career at the University of Illinois Hospital, and then headed up Abbott's hospital products division (now Hospira). Since joining the pharma side, she's led commercialization on several brands, including Humira, and in 2007 was named to lead the Rx biz.
Articles in this issue
over 18 years ago
Mightier Than the Swordover 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsover 18 years ago
Eric Floyd, Cephalonover 18 years ago
Nancy Phelan, Wyethover 18 years ago
Tightening the Chainover 18 years ago
Kurt Graves, Vertexover 18 years ago
Wendy Niebler, Shireover 18 years ago
Perfectly Imperfectover 18 years ago
Relaunching ReformAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5